Deactivating gene could boost immunotherapy for head and neck cancer
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
List view / Grid view
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
Researchers have developed a CAR T-cell engineering technique to ensure that only cancer cells are targeted, leaving healthy cells alone in solid tumours.
A team has revealed a function of ADAR1, responsible for RNA editing, discovering an isoform used for cancer growth, making it a drug target.
Researchers have shown that inhibiting Treg activation in tumours can provide effective immune responses without autoimmune toxicity.
CAR T cells modified to recognise CEACAM7 were able to eliminate pancreatic ductal adenocarcinoma cells in a late-stage model without toxic effects on healthy tissue.
Researchers have developed a novel CAR T-cell therapy for neuroblastoma which uses gating to limit toxicity and T-cell exhaustion.
A new form of CAR T-cell therapy has shown promise in mice models to treat blood cancers; this article delves into the development behind the therapy.
New insights into the mechanisms of anti-OX40 antibodies could enable their therapeutic activity to be manipulated to treat different tumours.
Researchers have discovered that in mice with cancers in the liver, immunotherapy and radiotherapy prevented T-cell death.
Immunology study shows that NF-kappa B-inducing kinase (NIK) is critical to T cell metabolism and the antitumour immune response.
Researchers were able to eradicate breast cancer in mice when they combined CAR T cells with STING pathway agonists and immunotherapeutic antibodies.
By combining natural killer cells with a new molecule called Sialyl-Lewis X, researchers were able to treat lymphoma in mice.
New research has provided a metabolic atlas for insights into obesity and tumours' ability to hide from the immune system.
A new cancer-killing virus called CF33 has shown success in pre-clinical trials, helping the immune system to eradicate tumours.
By combining machine learning and T-cell engineering researchers were able to develop cell therapies that can selectively and effectively target and destroy solid tumours.